Name
TT-R
Alternate names
None
Primary Site
None
Histology
None
Radiation
None
Remarks
None
Drugs for TT-R
Name
Alternate Names
11C topotecan
Hycamtin
SKF-104864
Topotecan Hydrochloride
Abbreviations
SKFS
Category
Chemotherapy
Subcategory
Topoisomerase inhibitor
NSC Number
609699
Primary Site
Histology
None
Remarks
Phase II (colorectal, NSCLC) Phase II/III SCLC Phase III MDS, ovarian Topoisomerase I inhibitor. FDA approved use on small cell lung cancer and ovarian cancer. GlaxoSmithKline.
Coding
This drug should be coded
Name
Alternate Names
Anti-CD20 monoclonal antibodies
C2B8 monoclonal antibody
IDEC-C2B8
MabThera
Monoclonal antibody IDEC-C2B8
Rituxan
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Cytostatic monoclonal antibody
NSC Number
687451
Primary Site
Leukemia
NHL
Histology
None
Remarks
December 2, 2021 The FDA approved rituximab (Rituxan, Genentech, Inc.) in combination with chemotherapy for pediatric patients (≥6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL).
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Rituximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Rituximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding as chemotherapy.
FDA approved 2/2006 for treatment of diffuse large B-cell, CD-20 positive non-Hodgkin lymphoma.
FDA approved 9/2006 for non-Hodgkin's B-cell lymphoma. Also used to treat autoimmune disorders, hemolytic anemia and ITP.
FDA approved 2/2010 for use in combination with cyclophosphamide and fludarabine in treatment of CLL.
FDA approved for maintenance therapy for previously untreated follicular CD-20 positive B-cell non-Hodgkin lymphoma who achieved response to rituximab in combination with chemotherapy.
June 22, 2017 FDA granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
.
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Rituximab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Rituximab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding as chemotherapy.
FDA approved 2/2006 for treatment of diffuse large B-cell, CD-20 positive non-Hodgkin lymphoma.
FDA approved 9/2006 for non-Hodgkin's B-cell lymphoma. Also used to treat autoimmune disorders, hemolytic anemia and ITP.
FDA approved 2/2010 for use in combination with cyclophosphamide and fludarabine in treatment of CLL.
FDA approved for maintenance therapy for previously untreated follicular CD-20 positive B-cell non-Hodgkin lymphoma who achieved response to rituximab in combination with chemotherapy.
June 22, 2017 FDA granted regular approval to the combination of rituximab and hyaluronidase human (RITUXAN HYCELA) for adult patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
.
Coding
This drug should be coded
Name
Alternate Names
BMS-181339-01
BMY-45622
Taxol
Abbreviations
None
Category
Chemotherapy
Subcategory
Mitotic inhibitor
plant alkaloid
Taxane
NSC Number
125973
673089
Primary Site
Histology
None
Remarks
Phase I (gastric) FDA approved uses on breast, ovarian, non-small cell lung cancers, and Kaposi's sarcoma. Bristol-Myers Squibb.
Coding
This drug should be coded